223 related articles for article (PubMed ID: 37128788)
1. Immunohistochemical evaluation of biomarkers with predictive role in acromegaly: a literature review.
Gliga MC; Tătăranu LG; Popescu M; Chinezu L; Paşcanu MI
Rom J Morphol Embryol; 2023; 64(1):25-33. PubMed ID: 37128788
[TBL] [Abstract][Full Text] [Related]
2. Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study.
Iacovazzo D; Carlsen E; Lugli F; Chiloiro S; Piacentini S; Bianchi A; Giampietro A; Mormando M; Clear AJ; Doglietto F; Anile C; Maira G; Lauriola L; Rindi G; Roncaroli F; Pontecorvi A; Korbonits M; De Marinis L
Eur J Endocrinol; 2016 Feb; 174(2):241-50. PubMed ID: 26586796
[TBL] [Abstract][Full Text] [Related]
3. Treatment of acromegaly in the era of personalized and predictive medicine.
Puig Domingo M
Clin Endocrinol (Oxf); 2015 Jul; 83(1):3-14. PubMed ID: 25640882
[TBL] [Abstract][Full Text] [Related]
4. Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience.
Brzana J; Yedinak CG; Gultekin SH; Delashaw JB; Fleseriu M
Pituitary; 2013 Dec; 16(4):490-8. PubMed ID: 23184260
[TBL] [Abstract][Full Text] [Related]
5. Pasireotide in the Personalized Treatment of Acromegaly.
Puig-Domingo M; Bernabéu I; Picó A; Biagetti B; Gil J; Alvarez-Escolá C; Jordà M; Marques-Pamies M; Soldevila B; Gálvez MA; Cámara R; Aller J; Lamas C; Marazuela M
Front Endocrinol (Lausanne); 2021; 12():648411. PubMed ID: 33796079
[TBL] [Abstract][Full Text] [Related]
6. Molecular and functional properties of densely and sparsely granulated GH-producing pituitary adenomas.
Mayr B; Buslei R; Theodoropoulou M; Stalla GK; Buchfelder M; Schöfl C
Eur J Endocrinol; 2013 Oct; 169(4):391-400. PubMed ID: 23847328
[TBL] [Abstract][Full Text] [Related]
7. PREDICTIVE MARKERS FOR POSTSURGICAL MEDICAL MANAGEMENT OF ACROMEGALY: A SYSTEMATIC REVIEW AND CONSENSUS TREATMENT GUIDELINE.
Ezzat S; Caspar-Bell GM; Chik CL; Denis MC; Domingue MÈ; Imran SA; Johnson MD; Lochnan HA; Grégoire Nyomba BL; Prebtani A; Ridout R; Ramirez JAR; Van Uum S
Endocr Pract; 2019 Apr; 25(4):379-393. PubMed ID: 30657362
[No Abstract] [Full Text] [Related]
8. Germline mutations of AIP gene in somatotropinomas resistant to somatostatin analogues.
Oriola J; Lucas T; Halperin I; Mora M; Perales MJ; Alvarez-Escolá C; Paz de MN; Díaz Soto G; Salinas I; Julián MT; Olaizola I; Bernabeu I; Marazuela M; Puig-Domingo M
Eur J Endocrinol; 2013 Jan; 168(1):9-13. PubMed ID: 23038625
[TBL] [Abstract][Full Text] [Related]
9. Impact of preoperative pasireotide therapy on invasive octreotide-resistant acromegaly.
Yamamoto R; Robert Shima K; Igawa H; Kaikoi Y; Sasagawa Y; Hayashi Y; Inoshita N; Fukuoka H; Takahashi Y; Takamura T
Endocr J; 2018 Oct; 65(10):1061-1067. PubMed ID: 30078825
[TBL] [Abstract][Full Text] [Related]
10. AIP and MEN1 mutations and AIP immunohistochemistry in pituitary adenomas in a tertiary referral center.
Daly AF; Cano DA; Venegas-Moreno E; Petrossians P; Dios E; Castermans E; Flores-Martínez A; Bours V; Beckers A; Soto-Moreno A
Endocr Connect; 2019 Apr; 8(4):338-348. PubMed ID: 30822274
[TBL] [Abstract][Full Text] [Related]
11. Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations.
Georgitsi M; Raitila A; Karhu A; Tuppurainen K; Mäkinen MJ; Vierimaa O; Paschke R; Saeger W; van der Luijt RB; Sane T; Robledo M; De Menis E; Weil RJ; Wasik A; Zielinski G; Lucewicz O; Lubinski J; Launonen V; Vahteristo P; Aaltonen LA
Proc Natl Acad Sci U S A; 2007 Mar; 104(10):4101-5. PubMed ID: 17360484
[TBL] [Abstract][Full Text] [Related]
12. Truncated somatostatin receptor 5 may modulate therapy response to somatostatin analogues--Observations in two patients with acromegaly and severe headache.
Marina D; Burman P; Klose M; Casar-Borota O; Luque RM; Castaño JP; Feldt-Rasmussen U
Growth Horm IGF Res; 2015 Oct; 25(5):262-7. PubMed ID: 26188991
[TBL] [Abstract][Full Text] [Related]
13. Pasireotide and Pegvisomant Combination Treatment in Acromegaly Resistant to Second-Line Therapies: A Longitudinal Study.
Chiloiro S; Bima C; Tartaglione T; Giampietro A; Gessi M; Lauretti L; Anile C; Colosimo C; Rindi G; Pontecorvi A; De Marinis L; Bianchi A
J Clin Endocrinol Metab; 2019 Nov; 104(11):5478-5482. PubMed ID: 31219586
[TBL] [Abstract][Full Text] [Related]
14. Clinical, hormonal and pathomorphological markers of somatotroph pituitary neuroendocrine tumors predicting the treatment outcome in acromegaly.
Tomasik A; Stelmachowska-Banaś M; Maksymowicz M; Czajka-Oraniec I; Raczkiewicz D; Zieliński G; Kunicki J; Zgliczyński W
Front Endocrinol (Lausanne); 2022; 13():957301. PubMed ID: 36187106
[TBL] [Abstract][Full Text] [Related]
15. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
[TBL] [Abstract][Full Text] [Related]
16. E-cadherin expression is associated with somatostatin analogue response in acromegaly.
Venegas-Moreno E; Flores-Martinez A; Dios E; Vazquez-Borrego MC; Ibañez-Costa A; Madrazo-Atutxa A; Japón MA; Castaño JP; Luque RM; Cano DA; Soto-Moreno A
J Cell Mol Med; 2019 May; 23(5):3088-3096. PubMed ID: 30843342
[TBL] [Abstract][Full Text] [Related]
17. Expression of somatostatin receptor subtypes in human pituitary adenomas -- immunohistochemical studies.
Pisarek H; Pawlikowski M; Kunert-Radek J; Radek M
Endokrynol Pol; 2009; 60(4):240-51. PubMed ID: 19753537
[TBL] [Abstract][Full Text] [Related]
18. Germline mutations of aryl hydrocarbon receptor-interacting protein (AIP) gene and somatostatin receptor 1-5 and AIP immunostaining in patients with sporadic acromegaly with poor versus good response to somatostatin analogues.
Ozkaya HM; Comunoglu N; Sayitoglu M; Keskin FE; Firtina S; Khodzhaev K; Apaydin T; Gazioglu N; Tanriover N; Oz B; Kadioglu P
Pituitary; 2018 Aug; 21(4):335-346. PubMed ID: 29455389
[TBL] [Abstract][Full Text] [Related]
19. Low aryl hydrocarbon receptor-interacting protein expression is a better marker of invasiveness in somatotropinomas than Ki-67 and p53.
Kasuki Jomori de Pinho L; Vieira Neto L; Armondi Wildemberg LE; Gasparetto EL; Marcondes J; de Almeida Nunes B; Takiya CM; Gadelha MR
Neuroendocrinology; 2011; 94(1):39-48. PubMed ID: 21178332
[TBL] [Abstract][Full Text] [Related]
20. Pathology of acromegaly.
Horvath E; Kovacs K
Neuroendocrinology; 2006; 83(3-4):161-5. PubMed ID: 17047379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
